All News
EULAR 2023: Featured Industry Presentations
EULAR 2023 opens tomorrow, Wednesday May 31st, with hundreds of novel presentations and pivotal clinical trials, many being featured industry sponsored clinical trials and research on their novel agents. Below is a collection of the featured abstracts, and presentation times from EULAR
Read Article
EULAR 2023 recommendations on the management of fatigue in IRMDs. 4 overarching principles and 4 recommendations for monitoring and assessment of fatigue, Dures E Abst#P0370 #EULAR2023 @RheumNow https://t.co/AirPlRLNjZ
Dr. Antoni Chan synovialjoints ( View Tweet)
In an early SpA (DESIR) cohort, the occurrence of a first pregnancy did not seem to increase the number of imaging abnormalities of the SIJ. Overall no significant changes in radiographic and MRI imaging abnormalities of the SIJ, Molto A, Abst#POS0303, #EULAR2023 @RheumNow
Dr. Antoni Chan synovialjoints ( View Tweet)
The incidence of MACEs at 8 years is low in AS patients treated with NSAIDs. Study of 22929 patients, NSAIDs (SHR: 0.40 [0.32-0.49], p<0.001) and anti-TNFs (SHR: 0.61 [0.47-0.81], p<0.001) associated with a lower risk of MACE, Fakih O, Abst#POS0301, #EULAR2023 @RheumNow https://t.co/i5GZMcJwyO
Dr. Antoni Chan synovialjoints ( View Tweet)
#EULAR2023 Clinical Highlights. SpA: OP0059 H2H RCT of SEC vs ADA Biosimilar in bDMARDs naive showed no difference in imaging progression at 2yrs.
OP0061 Pooled analyses of UPA RCTs showed low rates of Extra-articular Manifestation. Numerically lower vs PBO for Uveitis @RheumNow https://t.co/GoUPfpwTLq
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Tune it at 1pm EST for RheumNow's daily #EULAR23 recaps. You can find us live on Twitter, YouTube and LinkedIn. https://t.co/t531csjXo8
Dr. John Cush RheumNow ( View Tweet)
We need to assess CV risk in IA but how?
Performances of QRisk3, Framingham & Reynolds scores for prediction of CV event in OA RA PsA AS PSO
Bummer: these 3 prediction tools are less accurate in IA but also OA.
We need a dedicated tool.
@Rheumnow OP0267 #EULAR23 https://t.co/O73cETXXoe
Aurelie Najm AurelieRheumo ( View Tweet)
Just a reminder: nr-axSpA isn’t destined to become r-axSpA/AS. Life is more complicated than that.
Between the natural history and TNFi, very small conversion rate post-10y. Of course, whatever the x-rays, it can still disable though
DESIR cohort POS0675 #EULAR2023 @RheumNow https://t.co/29HeJXpK2S
David Liew drdavidliew ( View Tweet)
#EULAR2023 #OP0007 What are the recent trends of autoimmune disease (AID)? A database study (22m) in UK showed:
- 1 in 10 people had AID in the last 20yrs
- socioeconomic, seasonal & regional disparities cd influence pathogenesis
- CTD (SLE,pSS,SSc) tended to co-occur @RheumNow https://t.co/3DDPR2K5NC
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Chinese study 43 axSpA pts Rx w/ Secukinumab-37 pts had HBV & 16% (6) reactivated HBV after mean 9 mos of SEC (5 w/ chronic HBV, 1 occult HBV). 2 pts chronic HBV reactivated despite anti-HBV prophylaxis. 6 axSpA w/ LTBI - none had TB on SEC https://t.co/o4gA9mcD2R https://t.co/XKwp2z9U3K
Links:
Dr. John Cush RheumNow ( View Tweet)
Autoimmune disease diagnoses slowly on the rise, despite reduced smoking - but that’s now 10% of the population, & many patients have more than one. Most are lifelong.
Surely this needs more investment??
CPRD data from the UK #EULAR2023 OP0007 @RheumNow https://t.co/7NGF5YaE9z https://t.co/m6SaibqmEq
David Liew drdavidliew ( View Tweet)
AxSpA can be unequivocally diagnosed in the first 2 years of onset of chronic back pain with 30% definite with HLA-B27+ and imaging being the key SpA features from the SPACE cohort by
Mary Lucy Marques, Abst #OP0005 @RheumNow https://t.co/m5umD00hDf
Dr. Antoni Chan synovialjoints ( View Tweet)
With all the benefits of MRI and expert rheumatologists, do our diagnoses of axSpA stick, two years later?
Overwhelmingly yes, but sometimes we do actually have to change our minds. Beware the set and forget for our clinical diagnoses
SPACE cohort #EULAR2023 OP0005 @RheumNow https://t.co/AN6XzqKlv3
David Liew drdavidliew ( View Tweet)
There are lots of reasons why axSpA treatments fail for patients. And as rheumatologists, we can’t just prescribe and walk away - we need to address each in turn, for our patients’ sake #EULAR2023 @RheumNow https://t.co/hzo57BaEXw
David Liew drdavidliew ( View Tweet)
Vedolizumab (VED) doesnt help SpA. Study of 39 IBD, half on VED, 17 w/ SpA (7 axial). 14 w/ periph. arthritis before VED, only 3 improved w/ VED. 3 pts on VED developed new arthritis/aglas. 6 Pts stopped for SpA (2) or IBD (4) worsening. https://t.co/8BMTmJqhPq https://t.co/BOMsk38KB2
Links:
Dr. John Cush RheumNow ( View Tweet)
UK Biobank cohort study (n=361,952) assessed BMI effects on rheumatic Dz risk. Higher BMI incr odds of RA (IRR=1.52), OA (IRR=1.49), PsA (IRR=1.80), gout (1.73), SpA(1.34); more pronounced in women for both gout and psoriatic arthropathy https://t.co/eLeeShSSv1 https://t.co/IjWF2EPqOR
Links:
Dr. John Cush RheumNow ( View Tweet)
PREVENT study looked at Xray progression in 438 nr-axSpA pts given PBO or secukinumab. At baseline there was little SI damage & at 2 yrs no SI progression (− 0.04 mSASSS) or spinal inflammation in both groups. https://t.co/3EgnK2rWgb https://t.co/z5umUhpViF
Links:
Dr. John Cush RheumNow ( View Tweet)
MRI study of SI jts in axSpA 196 pts shows w/ increasing bone marrow edema of SI, SI damage is likely. BME each quadrant incr odds: sclerosis (OR:1.9), erosions (1.9). BME lead to 5 yr SIJ damage if fluctuating (OR:5.6) or persistent (OR:7.5) https://t.co/Dkbcij5Uhv https://t.co/x83kErVb1E
Links:
Dr. John Cush RheumNow ( View Tweet)
Save the date! We'll be tuning in live from Milan for EULAR '23. Count on us for:
-KOL perspective videos
-Clinical Trial Highlights
-Daily Faculty Recaps
-Live Streaming
and more! https://t.co/9uKnDTynfk
Dr. John Cush RheumNow ( View Tweet)
⚠️Beware not all bone marrow oedema =#AxSpA on MRI !
Signal seen in 17% volunteers at SIJs
@DrPoddubnyy
#RNL2023 https://t.co/xTKuSRXK72 https://t.co/c09QjSkJBP
Links:
Dr. John Cush RheumNow ( View Tweet)
